Can Giant Cell Arteritis (GCA) Be Cured Permanently?
At a Glance
While Giant Cell Arteritis (GCA) is not typically permanently cured, it is highly treatable. The goal of treatment is to achieve remission, where symptoms and inflammation are fully controlled. Even after stopping medication, lifelong monitoring is necessary to watch for relapses and complications.
In this answer
3 sections
Giant cell arteritis (GCA) is highly treatable and manageable, though it is not typically described as a condition that can be permanently “cured.” Instead, the medical goal is to reach remission—a state where your symptoms disappear, your blood test results return to normal, and the inflammation in your blood vessels is fully controlled. While many people successfully stop taking medication after a period of treatment, GCA is considered a chronic condition that requires lifelong awareness and regular monitoring.
Understanding Remission vs. Cure
In medicine, a “cure” generally means the disease is completely eradicated and will never return. Because GCA involves an abnormal immune system response that can sometimes reactivate, doctors focus on achieving and maintaining remission rather than a permanent cure [1][2].
When you are in remission, you may feel completely normal and healthy. However, relapse—when symptoms and inflammation return—is frequent, especially while your medication doses are being slowly lowered (tapered) or shortly after you stop taking them [3][2][4]. This often happens because the medication dose drops below the level needed to keep the immune system fully suppressed. Because of this risk, maintaining remission and preventing disease flares is the primary goal of your care team [5][6][1].
The Timeline for Medication
Treating GCA usually requires a long-term commitment. The standard initial treatment relies on glucocorticoids (steroids like prednisone) to quickly suppress the inflammation.
- The Tapering Process: Your doctor will gradually reduce your steroid dose over many months to find the lowest amount that keeps the disease controlled. This careful process aims to minimize the significant side effects of chronic steroid use, which can include bone loss (osteoporosis), weight gain, and increased blood sugar [1][2][7]. Your doctor may recommend calcium and vitamin D supplements to protect your bone health during this time.
- Duration: For many patients, the process of tapering off steroids takes 1 to 2 years, though it can take longer if relapses occur during the taper [1][7].
- Steroid-Sparing Medications: Today, doctors frequently use additional treatments alongside steroids. Medications like tocilizumab (an immune-suppressing biologic drug given by injection or IV) or methotrexate can help patients taper off steroids more rapidly and successfully achieve sustained remission without returning symptoms [5][8][9].
The Need for Lifelong Monitoring
Even after you have successfully stopped all medications and feel perfectly fine, your medical journey with GCA is not entirely over. Lifelong monitoring is a critical part of living with a history of GCA for two main reasons:
- Watching for Relapse: Symptoms can occasionally return even after treatment ends. You will always need to be alert to the classic warning signs of GCA, such as new or persistent headaches, scalp tenderness, or jaw pain when chewing [2]. Any changes in your vision require immediate, emergency medical attention, as they can be a sign of a severe flare that risks sudden, irreversible blindness. Routine blood tests to check your inflammatory markers (like ESR and CRP) will also be part of your long-term care to catch relapses early.
- Aortic Complications: GCA can cause inflammation in the aorta (the large artery carrying blood from the heart to the rest of the body). About 8% of people with GCA develop a thoracic aortic aneurysm—a dangerous ballooning or weakening of the aorta’s wall [10]. Importantly, some patients may have “smoldering” (silent, low-level) inflammation in their aorta even when their outer symptoms have stopped and they appear to be in full clinical remission [11]. Because aneurysms often cause no symptoms until they become severe, doctors recommend periodic imaging scans (like a CT, MRI, or PET scan) to monitor the health of your aorta over the long term [12][13]. You will likely start with a baseline scan at diagnosis and follow up according to a specific schedule set by your doctor.
While the word “cure” might not apply, a GCA diagnosis does not mean you will always feel sick. With careful treatment to reach remission and regular check-ups to protect your blood vessels, many people with GCA live normal, active lives long after their treatment ends.
Common questions in this guide
Can Giant Cell Arteritis be permanently cured?
How long do I need to take steroids for GCA?
What are the signs of a GCA relapse?
Why do I need imaging scans if my GCA is in remission?
Are there alternatives to taking steroids long-term for GCA?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my personal steroid tapering plan, and how frequently will we adjust the dose?
- 2.Are there steroid-sparing medications, like tocilizumab or methotrexate, that we should consider for my treatment plan?
- 3.What is the schedule for my routine blood tests (like ESR and CRP) to monitor for hidden inflammation?
- 4.When should we schedule my baseline imaging scan to check my aorta, and how often will we repeat it in the future?
- 5.Which specific symptoms should prompt me to go to the emergency room immediately versus calling the clinic?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (13)
- 1
Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis.
Mainbourg S, Addario A, Samson M, et al.
Arthritis care & research 2020; (72(6)):838-849 doi:10.1002/acr.23901.
PMID: 30951256 - 2
Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review.
Raleigh MF, Stoddard J, Darrow HJ
American family physician 2022; (106(4)):420-426.
PMID: 36260899 - 3
Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.
Camellino D, Matteson EL, Buttgereit F, Dejaco C
Nature reviews. Rheumatology 2020; (16(9)):481-495 doi:10.1038/s41584-020-0458-5.
PMID: 32759996 - 4
The Future of Giant Cell Arteritis Diagnosis and Management: A Systematic Review of Artificial Intelligence and Predictive Analytics.
Almadhoun MK, Yadav M, Shah SD, et al.
Cureus 2024; (16(12)):e75181 doi:10.7759/cureus.75181.
PMID: 39764337 - 5
Trial of Tocilizumab in Giant-Cell Arteritis.
Stone JH, Tuckwell K, Dimonaco S, et al.
The New England journal of medicine 2017; (377(4)):317-328 doi:10.1056/NEJMoa1613849.
PMID: 28745999 - 6
Tocilizumab in the treatment of giant cell arteritis.
Leuchten N, Aringer M
Immunotherapy 2018; (10(6)):465-472 doi:10.2217/imt-2017-0182.
PMID: 29504436 - 7
Relapses in giant cell arteritis: Updated review for clinical practice.
Alba MA, Kermani TA, Unizony S, et al.
Autoimmunity reviews 2024; (23(6)):103580 doi:10.1016/j.autrev.2024.103580.
PMID: 39048072 - 8
Should Tocilizumab Be Used Routinely in New Patients With a Diagnosis of Giant Cell Arteritis?
Sadun A, Gordon L
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2020; (40(1)):117-121 doi:10.1097/WNO.0000000000000869.
PMID: 31834197 - 9
Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study.
Unizony S, Matza MA, Jarvie A, et al.
The Lancet. Rheumatology 2023; (5(12)):e736-e742 doi:10.1016/S2665-9913(23)00265-5.
PMID: 38251564 - 10
Incidence and predictors of thoracic aortic damage in biopsy-proven giant cell arteritis.
Koster MJ, Crowson CS, Labarca C, Warrington KJ
Scandinavian journal of rheumatology 2021; (50(3)):239-242 doi:10.1080/03009742.2020.1786855.
PMID: 32940110 - 11
Persistent aortic inflammation in patients with giant cell arteritis.
Kaymakci MS, Boire NA, Bois MC, et al.
Autoimmunity reviews 2023; (22(9)):103411 doi:10.1016/j.autrev.2023.103411.
PMID: 37597603 - 12
Imaging Findings in Giant Cell Arteritis: Don't Turn a Blind Eye to the Obvious!
Bathla G, Agarwal AK, Messina SA, et al.
AJNR. American journal of neuroradiology 2025; (46(3)):457-464 doi:10.3174/ajnr.A8388.
PMID: 38906672 - 13
Visualization of cranial giant cell arteritis with [18F]FDG PET/CT: A case report.
Amjadeen MS, Bhatt M, Arnfield E
Radiology case reports 2024; (19(10)):4549-4553 doi:10.1016/j.radcr.2024.07.074.
PMID: 39206339
This page is for informational purposes only and does not replace professional medical advice. Always consult your healthcare provider about your GCA treatment plan and symptom monitoring.
Get notified when new evidence is published on Giant cell arteritis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.